monofer süste-/infusioonilahus
pharmacosmos a/s - raud(iii)derisomaltoos - süste-/infusioonilahus - 100mg 1ml 2ml 10tk; 100mg 1ml 1ml 1tk; 100mg 1ml 1ml 10tk; 100mg 1ml 2ml 5tk; 100mg 1ml 1ml 5tk
darunavir teva õhukese polümeerikattega tablett
teva b.v. - darunaviir - õhukese polümeerikattega tablett - 800mg 90tk; 800mg 100tk; 800mg 10tk
celsentri
viiv healthcare b.v. - maravirok - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.
dutrebis
merck sharp dohme limited - lamivudine, raltegravir kaaliumi - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebise on näidustatud kombinatsioonis teiste anti‑retroviral ravimitega inimese immuunpuudulikkuse viiruse (hiv‑1) infektsiooniga täiskasvanutel, noorukitel ja lastel alates 6 aastat ja kehakaaluga vähemalt 30 kg ilma praegu või varem anamneesis viirusevastaste ravimite insti (integraasi ülekande inhibiitorite) ja nrti (nukleosiidi pöördtranskriptaasi inhibiitorite) suhtes (vt lõigud 4 klassid. 2, 4. 4 ja 5.
epclusa
gilead sciences ireland uc - sofosbuvir, velpatasvir - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 ja 5.
harvoni
gilead sciences ireland uc - ledipasvir, sofosbuvir - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 ja 5. c-hepatiidi viiruse (hcv) genotüüp-eriaktiivsus vt lõigud 4. 4 ja 5.
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (vt punktid 4. 2, 4. 4 ja 5.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
opexa suus dispergeeruv tablett
menarini international operations luxembourg s.a. - bilastiin - suus dispergeeruv tablett - 10mg 30tk; 10mg 20tk; 10mg 50tk; 10mg 10tk
opexa tablett
menarini international operations luxembourg s.a. - bilastiin - tablett - 20mg 20tk; 20mg 10tk; 20mg 30tk; 20mg 50tk; 20mg 40tk